Post-traumatic osteonecrosis: Pathophysiology and advances in treatment strategies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Post-traumatic osteonecrosis represents one of the most feared complications following fractures that disrupt the vascular supply to vulnerable skeletal sites, leading to progressive bone death, structural collapse, and severe functional impairment. This research examined the pathophysiology, risk factor profiles, and comparative treatment outcomes of post-traumatic osteonecrosis across multiple anatomical locations in a Portuguese two-centre cohort. A prospective observational design enrolled 138 patients diagnosed with post-traumatic osteonecrosis at six skeletal sites between September 2022 and June 2023. Patients were categorised by the Association Research Circulation Osseous staging system and followed for 24 months following treatment initiation. Treatment modalities included core decompression, vascularised bone grafting, stem cell-augmented core decompression, total hip arthroplasty for advanced femoral head disease, and conservative management for patients who declined surgery or had contraindications. The femoral head was the most commonly affected site at 41.3%, followed by the talus at 18.1% and humeral head at 15.9%. Osteonecrosis severity demonstrated a time-dependent progression pattern, with mean ARCO severity scores increasing from 1.2 at six months post-injury to 3.7 beyond 36 months for the femoral head. Risk factor analysis identified vascular disruption as the highest contributor to disease severity across all ARCO stages, followed by high-energy trauma mechanism and fracture displacement. Stem cell-augmented core decompression produced the highest Harris Hip Scores at 24 months (81.7) for pre-collapse disease, while total hip arthroplasty yielded the best results for ARCO stage IV cases (87.3% success rate). Conservative management resulted in progressive functional deterioration across all stages. Treatment success rates declined sharply with advancing ARCO stage for all joint-preserving approaches, falling from 89.2% at ARCO stage I to 28.6% at ARCO stage IV for stem cell therapy. These findings confirm that post-traumatic osteonecrosis follows a predictable temporal trajectory that creates a narrow therapeutic window for joint-preserving interventions, and that biological augmentation strategies including stem cell therapy represent a promising advance over traditional surgical approaches for early-stage disease.
Fields of Study & Subjects
Bone and Joint Diseases
Bone fractures and treatments
Bone health and treatments
Publication details
- Journal / source
- International Journal of Orthopaedics and Traumatology
- Volume
- 8
- Issue
- 2
- Pages
- 04–10
- Publication date
- 1 February 2026
- Language
- EN